WO2015054439A3 - Hybrid factor viii polypeptides for use to treat hemophilia a - Google Patents
Hybrid factor viii polypeptides for use to treat hemophilia a Download PDFInfo
- Publication number
- WO2015054439A3 WO2015054439A3 PCT/US2014/059787 US2014059787W WO2015054439A3 WO 2015054439 A3 WO2015054439 A3 WO 2015054439A3 US 2014059787 W US2014059787 W US 2014059787W WO 2015054439 A3 WO2015054439 A3 WO 2015054439A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hrfviii
- bdd
- naturally occurring
- expression vectors
- domain deletion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Abstract
Hybrid recombinant FVIII polypeptides (hrFVIII) comprising non-naturally occurring combinations of amino acid modifications, cDNAs encoding such hrFVIII, expression vectors comprising nucleic acids encoding such hrFVIII, cells comprising expression vectors comprising nucleic acids encoding such hrFVIII, and methods of treating subjects having hemophilia A by administering to the subject such hrFVIII are disclosed herein. The non- naturally occurring amino acid modifications occur at sites of naturally occurring nonsynonymous-Single Nucleotide Polymorphisms (ns-SNP). The hrFVIII can be full length, having a B-domain deletion (BDD), having a B-domain deletion 2 (BDD-2), or having a B-domain deletion 3 (BDD-3). Methods of making the hrFVIIIs, cDNAs, expression vectors, cells are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888373P | 2013-10-08 | 2013-10-08 | |
US61/888,373 | 2013-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015054439A2 WO2015054439A2 (en) | 2015-04-16 |
WO2015054439A3 true WO2015054439A3 (en) | 2015-06-04 |
Family
ID=52813741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/059787 WO2015054439A2 (en) | 2013-10-08 | 2014-10-08 | Hybrid factor viii polypeptides for use to treat hemophilia a |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015054439A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
PE20231949A1 (en) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256062A1 (en) * | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
US20120297494A1 (en) * | 2009-10-16 | 2012-11-22 | Tommy Eugene Howard | Compositions and methods of treatment of black hemophiliac patients |
-
2014
- 2014-10-08 WO PCT/US2014/059787 patent/WO2015054439A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256062A1 (en) * | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
US20120297494A1 (en) * | 2009-10-16 | 2012-11-22 | Tommy Eugene Howard | Compositions and methods of treatment of black hemophiliac patients |
Also Published As
Publication number | Publication date |
---|---|
WO2015054439A2 (en) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
WO2015023891A3 (en) | Factor viii-xten fusions and uses thereof | |
PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
WO2011123830A3 (en) | Alpha 1-antitrypsin compositions and methods of making and using same | |
NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
BR112015021884A8 (en) | recombinant plasmid vectors, avv viral particle or plurality of viral particles, their production methods and uses, and pharmaceutical composition | |
EP2470559A4 (en) | Coagulation factor ix compositions and methods of making and using same | |
IL294314A (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
WO2011150133A3 (en) | Fibronectin based scaffold proteins having improved stability | |
WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
MX2011013183A (en) | Growth hormone polypeptides and methods of making and using same. | |
WO2012069655A3 (en) | Improved capping modules for designed ankyrin repeat proteins | |
EA033007B1 (en) | POLYPEPTIDE COMPRISING A LIPIDATED HETERODIMER OF MUTANT FRAGMENTS OF OspA, METHOD FOR PRODUCING THE POLYPEPTIDE AND USE THEREOF | |
WO2015054439A3 (en) | Hybrid factor viii polypeptides for use to treat hemophilia a | |
WO2015158749A3 (en) | Viral vector for the targeted transfer of genes in the brain and spinal cord | |
WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
MX2015007712A (en) | Short-acting factor vii polypeptides. | |
WO2014145524A3 (en) | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a | |
WO2015061464A3 (en) | Recombinant glycoproteins and uses thereof | |
MX2015012905A (en) | Recombinant factor viii formulations. | |
WO2014152247A8 (en) | Improved tnf binding proteins | |
WO2015108856A3 (en) | Methods for enhancing the delivery of active agents | |
AU2016341983A8 (en) | Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14851975 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14851975 Country of ref document: EP Kind code of ref document: A2 |